Peptide News Digest

#Cancer-Prevention

3 stories

Research · View digest

Annals of Oncology (June 7): GLP-1 RA Use Linked to 41% Lower Obesity-Associated Cancer Risk in 160,000-Patient TriNetX Target Trial Emulation

A target trial emulation of more than 160,000 patients, published online June 7, 2026 in Annals of Oncology and presented at ASCO 2026, reported that adults with obesity but without diabetes who received GLP-1 receptor agonists had a 41% lower risk of obesity-associated cancers compared with non-users. Subgroup signals included a 68% reduction in men and a 58% reduction in endometrial cancer. Lead author Arthur Heng-Cheng Hsu (Houston Methodist Neal Cancer Center) and colleagues examined 13 obesity-associated cancers across the TriNetX nationwide database. The findings extend prior signals from the SELECT trial (cardiovascular benefit) and FLOW (kidney benefit) into oncology and add empirical weight behind the 21-expert global panel proposal for a 10-year prospective GLP-1 cancer-prevention trial first surfaced at ECO 2026 in Istanbul.

Research · View digest

ECO 2026 Curtain-Raiser: 21-Expert Global Panel to Propose 10-Year GLP-1 Cancer Prevention Trial at Istanbul Congress (May 12–15)

Ahead of the European Congress on Obesity in Istanbul (May 12–15), a 21-expert global panel of obesity and cancer specialists will present a research proposal for a 10-year prospective trial testing GLP-1 receptor agonists like semaglutide and tirzepatide for prevention of obesity-related cancers. The proposal builds on the SELECT trial's established cardiovascular benefit, real-world dementia-incidence reductions, and the broader case that GLP-1s influence multiple aging-driven disease categories. The Istanbul meeting is the same venue where Novo Nordisk will present 52 abstracts on Wegovy, the higher-dose 7.2 mg formulation, the Wegovy pill, and CagriSema, including data on women's obesity, perimenopause, and migraine.